Author | Study groups (n) | Median (mean) Hospital Length of Stay (days) | Reported Significance (p-value or 95% CI) | Ref |
---|---|---|---|---|
Main findings | ||||
Brooklyn Antibiotic Resistance Task Force (2002)* | Carbapenem susceptible P. aeruginosa (10) | 20 (17) | 0.002 (0.001) | [60] |
Carbapenem resistant P. aeruginosa (10) | 33.5 (36) | |||
Eagye et al. (2009)* | Meropenem resistant P. aeruginosa (58) | 30 | <0.001 | [53] |
Meropenem susceptible P. aeruginosa (125) | 16 | |||
Meropenem resistant P. aeruginosa (58) | 30 | <0.001 | ||
Control (57) | 10 | |||
Evans et al. (2007)‡ | Susceptible P. aeruginosa (73) | 20 | 0.03 | [71] |
Resistant P. aeruginosae (47) | 26 | |||
Furtado et al. (2009)‡ | Imipenem resistant P. aeruginosa (63) | 25 | 0.006 | [62] |
Control (182) | 15 | |||
Gasink et al. (2006)* | Fluoroquinolone resistant P. aeruginosa (320) | 10 | 0.13 | [64] |
Fluoroquinolone susceptible P. aeruginosa (527) | 9 | |||
Kaminski et al. (2011)†| Ureido/carboxypenicillin resistant P. aeruginosa (70) | 50 | 0.24 | [66] |
Ureido/carboxypenicillin susceptible P. aeruginosa (153) | 47.5 | |||
Lautenbach et al. (2010)†| Imipenem resistant P. aeruginosa (253) | 16 | <0.001 | [63] |
Imipenem susceptible P. aeruginosa (2289) | 9 | |||
Morales et al. (2012)‡ | MDR P. aeruginosaf (134) | 39 (45.7) | <0.001a | [49] |
Susceptible P. aeruginosa (149) | 20 (25.1) | |||
Resistant P. aeruginosa (119) | 30 (39.0) | <0.001a | ||
Susceptible P. aeruginosa (149) | 20 (25.1) | |||
Paramythiotou et al. (2004)†| MDR P. aeruginosag (34) | 44.5 (57.0)b,d/11.1c,d | 0.28/0.81 | [54] |
Control (34) | 43.5 (46.9)b,d/5.8c,d | |||
Tam et al. (2010)†| MDR P. aeruginosah (25) | 26.4c | 0.12 | [13] |
Susceptible P. aeruginosa (84) | 16.5c |